p.70 抽出テキスト

priate implantable cardioverter defibrillator therapy in Japanese patients with multicenter automatic defibrillator implantation trial II criteria. J Arrhythm 2017; 33: 17-22. PMID: 28217224 41. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2022; 43: 3997-4126. PMID: 36017572 42. de Sousa MR, Morillo CA, Rabelo FT, et al. Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis. Eur J Heart Fail 2008; 10: 1007-1014. PMID: 18692437 43. Makimoto H, Zielke S, Clasen L, et al. Clinical significance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients. Eur J Med Res 2020; 25: 5. PMID: 32183891 44. Kinoshita T, Hashimoto K, Yoshioka K, et al. Risk stratification for cardiac mortality using electrocardiographic markers based on 24-hour Holter recordings: the JANIES-SHD study. J Cardiol 2020; 75: 155-163. PMID: 31474497 45. Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 2017; 5: 28-38. PMID: 28017348 46. Klem I, Klein M, Khan M, et al. Relationship of LVEF and myocardial scar to long-term mortality risk and mode of death in patients with nonischemic cardiomyopathy. Circulation 2021; 143: 1343- 1358. PMID: 33478245 47. Gigli M, Merlo M, Graw SL, et al. Genetic risk of arrhythmic phenotypes in patients with dilated cardiomyopathy. J Am Coll Cardiol 2019; 74: 1480-1490. PMID: 31514951 48. Muchtar E, Blauwet LA, Gertz MA. Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 2017; 121: 819-837. PMID: 28912185 49. 日本循環器学会.心臓サルコイドーシスの診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/ 2020/ 02/ JCS2016_terasaki_h.pdf 50. De Bortoli A, Birnie DH. Diagnosis and treatment of cardiac sarcoidosis. Circ J 2023; 87: 471-480. PMID: 36624070 51. Terasaki F, Kusano K, Nakajima T, et al. The characteristics of Japanese guidelines on diagnosis and treatment of cardiac sarcoidosis compared with the previous guidelines. Sarcoidosis Vasc Diffuse Lung Dis 2022; 39: e2022028. PMID: 36791038 52. Takaya Y, Nakamura K, Nishii N, et al. Clinical outcomes of patients with isolated cardiac sarcoidosis confirmed by clinical diagnostic criteria. Int J Cardiol 2021; 345: 49- 53. PMID: 34743890 53. Birnie DH, Nery PB, Ha AC, et al. Cardiac sarcoidosis. J Am Coll Cardiol 2016; 68: 411-421. PMID: 27443438 54. Banba K, Kusano KF, Nakamura K, et al. Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 2007; 4: 1292-1299. PMID: 17905334 55. Kusano KF, Satomi K. Diagnosis and treatment of cardiac sarcoidosis. Heart 2016; 102: 184-190. PMID: 26643814 56. Nagai T, Nagano N, Sugano Y, et al. Effect of corticosteroid therapy on long-term clinical outcome and left ventricular function in patients with cardiac sarcoidosis. Circ J 2015; 79: 1593-1600. PMID: 25877828 57. Nagai T, Nagano N, Sugano Y, et al. Effect of discontinuation of prednisolone therapy on risk of cardiac mortality associated with worsening left ventricular dysfunction in cardiac sarcoidosis. Am J Cardiol 2016; 117: 966-971. PMID: 26805658 58. Ekström K, Lehtonen J, Nordenswan HK, et al. Sudden death in cardiac sarcoidosis: an analysis of nationwide clinical and causeof-death registries. Eur Heart J 2019; 40: 3121- 3128. PMID: 31230070 59. Nabeta T, Kitai T, Naruse Y, et al. Risk stratification of patients with cardiac sarcoidosis: the ILLUMINATE-CS registry. Eur Heart J 2022; 43: 3450-3459. PMID: 35781334 60. Takaya Y, Kusano K, Nishii N, et al. Early and frequent defibrillator discharge in patients with cardiac sarcoidosis compared with patients with idiopathic dilated cardiomyopathy. Int J Cardiol 2017; 240: 302-306. PMID: 28438355 61. Kusano K, Ishibashi K, Noda T, et al. Prognosis and outcomes of clinically diagnosed cardiac sarcoidosis without positive endomyocardial biopsy findings. JACC Asia 2021; 1: 385-395. PMID: 36341209 62. Kandolin R, Lehtonen J, Airaksinen J, et al. Cardiac sarcoidosis:

epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 2015; 131: 624-632. PMID: 25527698 63 Nordenswan HK, Lehtonen J, Ekström K, et al. Outcome of

cardiac sarcoidosis presenting with high-grade atrioventricular block. Circ Arrhythm Electrophysiol 2018; 11: e006145. PMID: 30354309 64. Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol 2015; 115: 505-509. PMID: 25529542 65. Nadel J, Lancefield T, Voskoboinik A, et al. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 2015; 16: 634-641. PMID: 25617029 66. Ekström K, Lehtonen J, Hänninen H, et al. Magnetic resonance imaging as a predictor of survival free of life-threatening arrhythmias and transplantation in cardiac sarcoidosis. J Am Heart Assoc 2016; 5: e003040. PMID: 27139734 67. Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016; 9: e 003738. PMID: 26763280 68. Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis. JACC Cardiovasc Imaging 2017; 10: 411-420. PMID: 27450877 69. Okada DR, Smith J, Derakhshan A, et al. Electrophysiology study for risk stratification in patients with cardiac sarcoidosis and abnormal cardiac imaging. Int J Cardiol Heart Vasc 2019; 23: 100342. PMID: 31321283 70. Zipse MM, Tzou WS, Schuller JL, et al. Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function. J Cardiovasc Electrophysiol 2019; 30: 1939- 1948. PMID: 31257683 71. Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 2016; 9: e003353. PMID: 27301264 72. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63: 329-336. PMID: 24140661 73. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011; 4: 43-48. PMID: 21193539 74. Kron J, Sauer W, Schuller J, et al. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis. Europace 2013; 15: 347- 354. PMID: 23002195 75. Azoulay LD, Waintraub X, Haroche J, et al. Factors associated with implantable cardioverter defibrillators appropriate therapy in cardiac sarcoidosis: a meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37: 17-23. PMID: 33093765 76. Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electrophysiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol 2014; 25: 171-176. PMID: 24433308 77. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2018; 138: e 210-e 271. PMID: 29084733 78. Kamada H, Ishibashi K, Miyazaki Y, et al. Fatal arrhythmic risks in cardiac sarcoidosis with mildly impaired cardiac function. JACC Asia 2023; 3: 755-763. PMID: 38094999 79. Stevenson A, Bray JJH, Tregidgo L, et al. Prognostic value of late gadolinium enhancement detected on cardiac magnetic resonance in cardiac sarcoidosis. JACC Cardiovasc Imaging 2023; 16: 345-357. PMID: 36752432 80. Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol 2014; 7: 1109-1115. PMID: 25266311 81. Ise T, Hasegawa T, Morita Y, et al. Extensive late gadolinium

enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after